Synairgen (LON:SNG) Hits New 52-Week Low – Time to Sell?

Synairgen plc (LON:SNG)’s stock price reached a new 52-week low on Thursday . The stock traded as low as GBX 0.60 ($0.01) and last traded at GBX 0.80 ($0.01), with a volume of 3092323 shares. The stock had previously closed at GBX 0.94 ($0.01).

Synairgen Trading Down 14.9 %

The firm has a 50-day simple moving average of GBX 2.03 and a two-hundred day simple moving average of GBX 3.34. The stock has a market cap of £7.82 million, a P/E ratio of -0.48 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).